Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· April 22, 2026

Stocks Settle Higher as Nasdaq Posts a Record High on Tech Strength

View original at nasdaq.com
Stocks Settle Higher as Nasdaq Posts a Record High on Tech Strength The S&P 500 Index ($SPX) (SPY) on Wednesday closed up +1.05%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.69%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.73%…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Double-upgraded Twilio to buy from underperform with a price target of $190

    60% confidence
  • Stripping out the technology sector, Q1 earnings are projected to increase around +3%, the weakest in two years

    60% confidence
  • The ECB shouldn't raise interest rates at its April meeting, but can't rule out a rate hike later this year

    60% confidence
  • Raising full-year adjusted gross margin forecast to 67.5%-68.5% from prior estimate of 67%-68%

    60% confidence
  • Will not reopen the strait or restart peace talks until the US blockade ends

    60% confidence
  • Upgraded UnitedHealth Group to buy from hold with a price target of $400

    60% confidence
  • There is no urgency for the ECB to raise interest rates from 2%, as the current data does not yet justify a move

    60% confidence
  • US naval blockade of the Strait of Hormuz will remain

    60% confidence
  • Q1 S&P 500 earnings are projected to climb +12% y/y

    60% confidence
  • Sees full-year adjusted EPS at the low end of a $5.80 to $6.20 range

    60% confidence
  • Forecasts Q2 net sales of $3.25 billion to $3.45 billion

    60% confidence
  • Cut full-year adjusted EPS estimate to $7.00 to $11.00 from previous estimate of $12.00 to $14.00

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com